Core Viewpoint - Vista Gold Corp. has announced a public offering of 15,600,000 common shares priced at US$2.50 per share, aiming to raise approximately US$39.0 million before expenses [1][2]. Offering Details - The offering is expected to close on March 9, 2026, pending customary closing conditions and approvals from the NYSE American and the Toronto Stock Exchange [2]. - Vista has granted underwriters a 30-day option to purchase an additional 2,340,000 common shares to cover over-allotments [2]. Use of Proceeds - The net proceeds from the offering will be allocated to advance exploration and development activities at the Mt. Todd gold project in Australia's Northern Territory, as well as for general corporate purposes [3]. Underwriters and Regulatory Compliance - CIBC Capital Markets is the sole bookrunner for the offering, with BMO Capital Markets, Raymond James, H.C. Wainwright & Co., and Tamesis Partners acting as co-managers [3]. - The offering is made under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4]. Additional Information - The offering is being conducted in Canada, excluding Quebec, under the "listed issuer financing" exemption [5]. - The Company intends to rely on exemptions set forth in the TSX Company Manual for this offering [6]. Company Overview - Vista Gold Corp. holds the Mt. Todd gold project, a significant development-stage gold deposit located in a Tier-1 mining jurisdiction in Northern Territory, Australia [8]. - The Mt. Todd project is characterized by strong project economics, significant initial production potential, and opportunities for expansion and exploration [9].

Core Viewpoint - Novo Resources Corp. has announced a capital raising initiative aimed at raising gross proceeds of C$7.9 million (approximately A$8.2 million) through a placement of units and Chess Depository Interests (CDIs) to institutional and sophisticated investors [3][9]. Group 1: Capital Raising Details - The capital raising will involve the issuance of approximately 16.8 million units at C$0.10 per unit and approximately 61.1 million CDIs at A$0.105 per CDI [3]. - The placement will occur in two tranches, with Tranche 1 expected to raise approximately C$6.0 million (around A$6.2 million) and Tranche 2 expected to raise approximately C$1.9 million (around A$2.0 million), subject to shareholder approval [11]. - Major shareholder Northern Star Ltd has committed to participate in the placement up to its pro-rata holding of approximately 9% [5]. Group 2: Use of Proceeds - The funds raised are intended to be primarily used for planned drilling and reconnaissance activities across priority projects throughout 2026, as well as for general working capital purposes [9]. - Drilling will focus on high-priority projects in Western Australia, including Wyloo, Balla Balla, and Teichman, with programs set to commence in Q2 2026 [10][18]. Group 3: Project Highlights - At Wyloo, a proposed 1,500m RC drill program will target a high-grade vein array, with peak rock chip assays returning 0.93 g/t Au, 482 g/t Ag, 1.29% Sb, 2.62% Cu, 9.7% Pb, and 15.95% Zn [10]. - The Balla Balla project will see a planned 6,000m AC drill program aimed at expanding on a previously completed 5,996m Air Core drill program that identified a large polymetallic geochemical anomaly [18]. - The Teichman project will have a planned 2,000m RC drill program focusing on two shear zones that returned significant gold assays [18]. Group 4: Additional Information - Novo continues to receive strong annual dividends from its investment in the San Cristobal Mine, which has delivered excellent returns [13]. - The company has a significant land package covering approximately 4,160 square kilometers in the Pilbara region of Western Australia and is focused on discovering standalone gold and copper projects with over 1 million ounces of development potential [21].

TAIPEI, Taiwan, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Asia Pacific Wire & Cable Corporation Limited (“APWC” or “Company”) (NASDAQ: APWC) today announced the successful completion and final results of its rights offering, as described in the rights offering prospectus filed December 18, 2025 with the Securities and Exchange Commission ("Rights Offering"). Of the 20,616,227 maximum issuable shares, shareholders exercising their basic and over-subscription rights acquired 18,165,738 Common Shares and the remaining ...

The State of DevSecOps Report 2026 highlights a broader industry shift as security risk increasingly moves upstream into the software supply chainNEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Datadog, Inc. (NASDAQ: DDOG), the AI-powered observability and security platform for cloud applications, today released its latest State of DevSecOps Report, finding that nearly nine in 10 organizations (87%) have at least one known exploitable vulnerability in deployed services. The report points to a broader industry s ...

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofrontera’s filings ...

LONDON, February 26, 2026 – Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that the Company's Board of Directors recommended a final dividend for 2025 of $1.00 per Common Share, payable on May 6, 2026 to shareholders of record as of April 22, 2026. The shares will trade ex-dividend on and after April 21, 2026. The dividend, which is subject to shareholder approval, will be voted on at the Company's Annual General Meeting of Shareholders scheduled for April 16, 2026 in Bermuda. If approved, this will ...

Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and developmentTAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Ce ...

Geneva, Switzerland, Feb. 26, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that it will present its Quantum Security technology and strategic roadmap at the Cantor Global Technology & Industrial Growth Conference, taking place from March 10–11, 2026, at the New York Hilton Hotel in NYC. SEALSQ’s CEO, Carlos Moreira, will participat ...

By combining Thomas’s sourcing technology and marketing tools with Maryland MEP’s reach, the partnership aims to fortify the Maryland supply chain and position local manufacturers for growthNORTH BETHESDA, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Thomas, a leading digital platform connecting industrial buyers with more than 500,000 suppliers, announced a strategic partnership with Maryland Manufacturing Extension Partnership (Maryland MEP) to accelerate the growth and digital maturity of manufacturers across ...

Core Insights - TIAN RUIXIANG Holdings Ltd. has significantly increased its Bitcoin investment from 15,000 to 30,000 BTC, reflecting strong confidence in its strategic vision and positioning in the AI-crypto landscape [1][2]. Group 1: Strategic Partnership and Investment - The strategic investor has committed an additional 15,000 BTC, bringing the total investment to 30,000 BTC, valued at over $2.0 billion at current market prices [2]. - This investment enhances TIRX's balance sheet with a highly liquid digital asset, reinforcing the investor's belief in TIRX's potential to innovate in AI-driven finance [2][5]. Group 2: Innovation and Product Development - The expanded partnership will accelerate the development of next-generation solutions, including AI-powered crypto trading and risk management systems [3][4]. - TIRX aims to create scalable and secure decentralized application ecosystems and innovative AI-crypto fusion products tailored for both institutional and retail investors [4]. Group 3: Market Position and Future Outlook - With the revised agreement, TIRX solidifies its position as a leader in the AI-crypto convergence, gaining financial resilience and strategic flexibility for aggressive expansion [5]. - The company views market corrections as opportunities for growth, positioning itself to lead the AI-crypto revolution for the long term [6].